메뉴 건너뛰기




Volumn 4, Issue 3, 2004, Pages 285-299

Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ADENOSINE TRIPHOSPHATE; ALPHA INTERFERON; BCR ABL PROTEIN; BORTEZOMIB; CYTARABINE; CYTOTOXIC AGENT; ERYTHROMYCIN; HISTONE DEACETYLASE INHIBITOR; IMATINIB; LAQ 284; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 1; MUTANT PROTEIN; OROSOMUCOID; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; SK 1606; STAT5 PROTEIN; STEM CELL FACTOR RECEPTOR; SYNAPTOPHYSIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; WT1 PROTEIN; ANTINEOPLASTIC AGENT; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

EID: 2342629325     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557043487321     Document Type: Review
Times cited : (170)

References (133)
  • 73
    • 0001453447 scopus 로고    scopus 로고
    • Ojima I, Vite G, Altmann K (Eds.), ACS Symposium Series 796. Washington, DC: American Chemical Society
    • Zimmermann, J.; Furet, P.; Buchdunger E. In: Ojima I, Vite G, Altmann K (Eds.), Anticancer Agents: Frontiers in Cancer Chemotherapy. ACS Symposium Series 796. Washington, DC: American Chemical Society, 2001, pp. 245-259.
    • (2001) Anticancer Agents: Frontiers in Cancer Chemotherapy , pp. 245-259
    • Zimmermann, J.1    Furet, P.2    Buchdunger, E.3
  • 122
    • 0036399997 scopus 로고    scopus 로고
    • Combination therapy with imatinib mesylate (STI571): Synopsis of in in vitro studies
    • Topaly, J.; Zeller, W. J.; Fruehauf, S.; Combination therapy with imatinib mesylate (STI571): Synopsis of in in vitro studies. Br. J. Hematol. 2002, 119, 3-14.
    • (2002) Br. J. Hematol. , vol.119 , pp. 3-14
    • Topaly, J.1    Zeller, W.J.2    Fruehauf, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.